R Marchioli

Summary

Affiliation: Consorzio Mario Negri Sud
Country: Italy

Publications

  1. ncbi request reprint The haematocrit and platelet target in polycythemia vera
    Marcello Di Nisio
    Department of Medicine and Aging, School of Medicine, and Aging Research Centre, Ce S I, Gabriele D Annunzio University Foundation, Chieti Pescara, Italy
    Br J Haematol 136:249-59. 2007
  2. pmc Why Do We Still Need Large Scale Clinical Trial: The Case of n-3 PUFA
    Roberto Marchioli
    Laboratory of Clinical Epidemiology of Cardiovascular Disease, Consorzio Mario Negri Sud Chieti, Italy
    Front Physiol 3:202. 2012
  3. pmc The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
    Roberto Marchioli
    CYTO PV Coordinating Center, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy
    Thrombosis 2011:794240. 2011
  4. pmc Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease
    Giacomo Levantesi
    Laboratory of Clinical Epidemiology of Cardiovascular Disease, Consorzio Mario Negri Sud, Chieti, Italy
    J Multidiscip Healthc 3:79-96. 2010
  5. doi request reprint n-3 PUFAs in cardiovascular disease
    Roberto Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy Electronic address
    Int J Cardiol 170:S33-8. 2013
  6. doi request reprint n-3 PUFAs and heart failure
    Roberto Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy Electronic address
    Int J Cardiol 170:S28-32. 2013
  7. doi request reprint Cardiovascular events and intensity of treatment in polycythemia vera
    Roberto Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    N Engl J Med 368:22-33. 2013
  8. pmc Methodological approach for the assessment of ultrasound reproducibility of cardiac structure and function: a proposal of the study group of Echocardiography of the Italian Society of Cardiology (Ultra Cardia SIC) part I
    Maurizio Galderisi
    Department of Clinical and Experimental Medicine, Federico II University Hospital, Via S, Pansini 5, 80131, Naples, Italy
    Cardiovasc Ultrasound 9:26. 2011
  9. ncbi request reprint Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial
    Roberto Marchioli
    Laboratory of Clinical Epidemiology of Cardiovascular Disease, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S Maria Imbaro Ch, Italy
    J Cardiovasc Med (Hagerstown) 7:347-50. 2006
  10. ncbi request reprint Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial
    R Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    J Membr Biol 206:117-28. 2005

Detail Information

Publications50

  1. ncbi request reprint The haematocrit and platelet target in polycythemia vera
    Marcello Di Nisio
    Department of Medicine and Aging, School of Medicine, and Aging Research Centre, Ce S I, Gabriele D Annunzio University Foundation, Chieti Pescara, Italy
    Br J Haematol 136:249-59. 2007
    ..Our findings do not suggest that the range of haematocrit (<55%) and platelet counts (<600 x 10(9)/l) we encountered in our population had an impact on the outcome of PV patients treated by current therapeutic strategies...
  2. pmc Why Do We Still Need Large Scale Clinical Trial: The Case of n-3 PUFA
    Roberto Marchioli
    Laboratory of Clinical Epidemiology of Cardiovascular Disease, Consorzio Mario Negri Sud Chieti, Italy
    Front Physiol 3:202. 2012
    ....
  3. pmc The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
    Roberto Marchioli
    CYTO PV Coordinating Center, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy
    Thrombosis 2011:794240. 2011
    ....
  4. pmc Uses and benefits of omega-3 ethyl esters in patients with cardiovascular disease
    Giacomo Levantesi
    Laboratory of Clinical Epidemiology of Cardiovascular Disease, Consorzio Mario Negri Sud, Chieti, Italy
    J Multidiscip Healthc 3:79-96. 2010
    ..The pharmacokinetic and pharmacodynamic properties of omega-3 ethyl esters, as well as evidence concerning their safety and tolerability, are also reported...
  5. doi request reprint n-3 PUFAs in cardiovascular disease
    Roberto Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy Electronic address
    Int J Cardiol 170:S33-8. 2013
    ....
  6. doi request reprint n-3 PUFAs and heart failure
    Roberto Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy Electronic address
    Int J Cardiol 170:S28-32. 2013
    ..However, further large clinical trials are undoubtedly needed to give adequate answers to still open questions on the treatment of HF. ..
  7. doi request reprint Cardiovascular events and intensity of treatment in polycythemia vera
    Roberto Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    N Engl J Med 368:22-33. 2013
    ..Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial...
  8. pmc Methodological approach for the assessment of ultrasound reproducibility of cardiac structure and function: a proposal of the study group of Echocardiography of the Italian Society of Cardiology (Ultra Cardia SIC) part I
    Maurizio Galderisi
    Department of Clinical and Experimental Medicine, Federico II University Hospital, Via S, Pansini 5, 80131, Naples, Italy
    Cardiovasc Ultrasound 9:26. 2011
    ..These procedures can be suggested for utilization also in non referall echocardiographic laboratories as an "inside" quality check, with the aim at optimizing clinical consistency of echo-Doppler data...
  9. ncbi request reprint Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial
    Roberto Marchioli
    Laboratory of Clinical Epidemiology of Cardiovascular Disease, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S Maria Imbaro Ch, Italy
    J Cardiovasc Med (Hagerstown) 7:347-50. 2006
    ..Recently, the HOPE trial showed an increment of the incidence of congestive heart failure (CHF) in patients treated with vitamin E...
  10. ncbi request reprint Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial
    R Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    J Membr Biol 206:117-28. 2005
    ....
  11. doi request reprint Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial
    Roberto Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    Expert Rev Cardiovasc Ther 7:735-48. 2009
    ..9 years to avoid one death or one cumulative event. Both drugs were safe and were tolerated. A simple and safe treatment with n-3 PUFA provides a beneficial advantage in patients with heart failure in a context of usual care...
  12. ncbi request reprint High pulse pressure and low mean arterial pressure: two predictors of death after a myocardial infarction
    Fausto Avanzini
    Department of Cardiovascular Research, Istituto Mario Negri, Milan, Italy
    J Hypertens 24:2377-85. 2006
    ..The aim of this study was to investigate the prognostic significance of different BP indices in post-MI...
  13. ncbi request reprint Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial
    Roberto Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro CH, Italy
    J Cardiovasc Med (Hagerstown) 8:S34-7. 2007
    ..We found no evidence that concomitant disease states, habits, or interventions altered the therapeutic benefit of n-3 PUFA consumption in survivors of recent myocardial infarction...
  14. ncbi request reprint Omega-3 fatty acids and heart failure
    Roberto Marchioli
    Consorzio Mario Negri Sud, Via Nazionale, Santa Maria Imbaro, Italy
    Curr Atheroscler Rep 11:440-7. 2009
    ..This article reviews recent clinical and experimental evidence on the effect of n-3 PUFA in coronary heart disease, with particular attention on HF and its pathophysiologic mechanisms...
  15. ncbi request reprint N-3 polyunsaturated fatty acids in heart failure: mechanisms and recent clinical evidence
    R Marchioli
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    Cell Mol Biol (Noisy-le-grand) 56:110-30. 2010
    ....
  16. ncbi request reprint Clinical trials in myeloproliferative disorders: looking forward
    Roberto Marchioli
    Laboratory of Epidemiology of Cardiovascular Disease, Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8, 66030 Santa Maria Imbaro, Chieti, Italy
    Semin Hematol 42:259-65. 2005
    ....
  17. ncbi request reprint Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione
    Roberto Marchioli
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    Circulation 105:1897-903. 2002
    ..Our purpose was to assess the time course of the benefit of n-3 polyunsaturated fatty acids (PUFAs) on mortality documented by the GISSI-Prevenzione trial in patients surviving a recent (<3 months) myocardial infarction...
  18. ncbi request reprint Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
    Roberto Marchioli
    European Collaboration on Low Dose Aspirin in Polycythemia Vera Coordinating Centre, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy
    J Clin Oncol 23:2224-32. 2005
    ..The aim of this study was to assess the rate of these complications in subjects receiving currently recommended treatments...
  19. ncbi request reprint Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data
    R Marchioli
    Laboratory of Clinical Epidemiology of Cardiovascular Disease, Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, Santa Maria Imbaro Chieti, Italy
    Lipids 36:S53-63. 2001
    ..Currently ongoing are several large-scale clinical trials that will help in clarifying the role of vitamin E in association with other antioxidants in the prevention of atherosclerotic coronary disease...
  20. ncbi request reprint Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial
    M G Franzosi
    Department of Cardiovascular Research, Istituto di Richerche Farmacologiche Mario Negri, Milano, Italy
    Pharmacoeconomics 19:411-20. 2001
    ..To estimate the cost effectiveness of treatment with n-3 polyunsaturated fatty acids (PUFA) for secondary prevention after myocardial infarction (MI)...
  21. ncbi request reprint Metabolic syndrome and risk of cardiovascular events after myocardial infarction
    Giacomo Levantesi
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    J Am Coll Cardiol 46:277-83. 2005
    ..We aimed to assess the prevalence and prognostic role of metabolic syndrome (METS) and diabetes in post-myocardial infarction (MI) patients...
  22. ncbi request reprint Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial
    F Barzi
    Department of Clinical Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    Eur J Clin Nutr 57:604-11. 2003
    ..To ascertain whether simple dietary advice to increase the consumption of Mediterranean foods, given in a clinical setting, leads to reduced mortality after a myocardial infarction...
  23. ncbi request reprint [Coffee and cardiovascular disease risk: yin and yang]
    Maria Giuseppina Silletta
    Laboratorio di Epidemiologia Clinica delle Malattie Cardiovascolari, Consorzio Mario Negri Sud, Santa Maria Imbaro
    Recenti Prog Med 99:533-7. 2008
    ..As it is not reasonable to conduct randomized controlled trials, it is recommended that coffee consumption be moderate in healthy people and limited in individuals at high risk...
  24. doi request reprint Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed
    Alejandro Macchia
    Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale 8, Santa Maria Imbaro, Chieti, Italy
    Am Heart J 159:245-57. 2010
    ..Since that last review, 10 new clinical trials with about 1,500 patients have been published, which has increased the statistical power of our observations...
  25. ncbi request reprint A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology
    Alejandro Macchia
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    Am Heart J 153:1037-47. 2007
    ..Neither their comparative efficacy on surrogate end points nor the overall impact on mortality have been formally reviewed...
  26. ncbi request reprint [Omega-3 polyunsaturated fatty acids and cardiovascular diseases]
    R Marchioli
    Laboratorio di Epidemiologia Clinica delle Malattie Cardiovascolari, Dipartimento di Farmacologia Clinica e Epidemiologia, Consorzio Mario Negri Sud, Santa Maria Imbaro CH, Italy
    Minerva Cardioangiol 51:561-76. 2003
    ....
  27. ncbi request reprint Coffee consumption and risk of cardiovascular events after acute myocardial infarction: results from the GISSI (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)-Prevenzione trial
    Maria Giuseppina Silletta
    Laboratory of Clinical Epidemiology of Cardiovascular Disease, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    Circulation 116:2944-51. 2007
    ..The relation between coffee consumption and cardiovascular disease has been studied extensively, but results are still debated. In addition, little evidence is available on patients with established coronary heart disease...
  28. ncbi request reprint Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids
    Alejandro Macchia
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    Eur J Heart Fail 7:904-9. 2005
    ..In GISSI-Prevenzione, treatment with n-3 polyunsaturated fatty acids (PUFA) reduced M and SD in post-MI patients, but their effect in patients with SyD is unknown...
  29. ncbi request reprint A clinically practicable diagnostic score for metabolic syndrome improves its predictivity of diabetes mellitus: the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI)-Prevenzione scoring
    Alejandro Macchia
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    Am Heart J 151:754.e7-754.e17. 2006
    ..We aimed to generate a diagnostic score for MS (MS-Score), aimed at predicting diabetes by giving appropriate weight to the individual components of MS...
  30. ncbi request reprint Meta-analysis of effect of statin treatment on risk of sudden death
    Giacomo Levantesi
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti, Italy
    Am J Cardiol 100:1644-50. 2007
    ..In subgroup analysis, the benefit of statins was independent from the main characteristics of the studies and changes in patient lipid levels during the study. In conclusion, our results suggest that statins decrease the risk of SCD...
  31. ncbi request reprint [Determinants of late-onset heart failure in myocardial infarction survivors: GISSI Prevenzione trial results]
    Alejandro Macchia
    Departamento de Farmacología Clínica y Epidemiología, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italia
    Rev Esp Cardiol 58:1266-72. 2005
    ..The factors predicting LHF are not well understood. Our aims were to identify the factors predicting LHF and to determine the survival rate in these patients...
  32. doi request reprint Levels of circulating pro-angiogenic cells predict cardiovascular outcomes in patients with chronic heart failure
    Giovanna Balconi
    Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research, Milano, Italy
    J Card Fail 15:747-55. 2009
    ..A low level of PACs is associated with worse outcome in patients with coronary heart disease. However, little is known about PACs in heart failure (HF)...
  33. doi request reprint Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial
    Serge Masson
    Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Circ Heart Fail 3:65-72. 2010
    ..There is, however, only limited information on the prevalence and prognostic role of urinary albumin excretion in patients with established chronic heart failure...
  34. ncbi request reprint Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
    Guido Finazzi
    Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy
    Blood 105:2664-70. 2005
    ..84-16.25; P = .0023), but not to hydroxyurea (HU) alone (HR, 0.86; 95% CI, 0.26-2.88; P = .8021), had an independent role in producing an excess risk for progression to AML/MDS compared with treatment with phlebotomy or interferon...
  35. ncbi request reprint Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
    Alessandro M Vannucchi
    Department of Hematology, University of Florence, 50134 Florence, Italy
    Blood 110:840-6. 2007
    ..We conclude that JAK2 617V>F homozygosity identifies PV or ET patients with a more symptomatic myeloproliferative disorder and is associated with a higher risk of major cardiovascular events in patients with ET...
  36. ncbi request reprint Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids
    Delia Di Stasi
    Department of Molecular Biochemistry and Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy
    Eur J Clin Pharmacol 60:183-90. 2004
    ..The aim of this study was to investigate the time course and the extent of incorporation of n-3 fatty acids in plasma and blood cells after 1 g/day of n-3 PUFA, the dose effective in the GISSI-Prevenzione in comparison with higher doses...
  37. ncbi request reprint Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors
    Dariush Mozaffarian
    Department of Medicine, Harvard Medical School and Harvard School of Public Health, Boston, MA 02115, USA
    Lancet 370:667-75. 2007
    ..We set out to estimate this incidence and investigate whether lifestyle factors such as dietary habits might alter this risk...
  38. ncbi request reprint Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure
    Luigi Tavazzi
    Policlinico San Matteo, IRCCS, Pavia, Italy
    Eur J Heart Fail 6:635-41. 2004
    ..The GISSI Heart Failure project is a large-scale, randomized, double-blind study designed to investigate the effects of n-3 polyunsaturated fatty acids and rosuvastatin on mortality and morbidity in patients with symptomatic heart failure...
  39. pmc Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level
    Daria Roccatagliata
    Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
    Vasc Health Risk Manag 2:507-14. 2006
    ..To assess the pharmacological treatment and the control of major modifiable cardiovascular risk factors in everyday practice according to the patients' cardiovascular risk level...
  40. ncbi request reprint GlObal Secondary Prevention strategiEs to Limit event recurrence after myocardial infarction: the GOSPEL study. A trial from the Italian Cardiac Rehabilitation Network: rationale and design
    Pantaleo Giannuzzi
    Salvatore Maugeri Foundation, IRCCS, Veruno, Italy
    Eur J Cardiovasc Prev Rehabil 12:555-61. 2005
    ....
  41. doi request reprint Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments
    Valerio De Stefano
    Institute of Hematology, Catholic University, Largo Gemelli 8, 00168 Rome, Italy
    Haematologica 93:372-80. 2008
    ..Prior thrombosis is a well-established risk factor for re-thrombosis in polycythemia vera and essential thrombocythemia but scarce data are available on the rate of re-thrombosis and the optimal strategy for prevention of recurrence...
  42. ncbi request reprint Efficacy and safety of low-dose aspirin in polycythemia vera
    Raffaele Landolfi
    Catholic University School of Medicine, Rome, Italy
    N Engl J Med 350:114-24. 2004
    ..The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial...
  43. ncbi request reprint Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects
    Cristofaro Raimondo De
    Hemostasis Research Center, Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy
    Thromb Haemost 87:58-67. 2002
    ..This may open the way to further studies aimed at elucidating the mechanisms by which the oxidative stress is linked to activation of the coagulation system in atherothrombotic disorders...
  44. ncbi request reprint Analysis of the benefits of a Mediterranean diet in the GISSI-Prevenzione study: a case study in imputation of missing values from repeated measurements
    Federica Barzi
    The George Institute for International Health, University of Sydney, Sydney, Australia
    Eur J Epidemiol 21:15-24. 2006
    ....
  45. ncbi request reprint Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study
    Benedetta D Chiodini
    Division of Genetics and Molecular Medicine, King s College London, London, UK
    Eur Heart J 28:1977-83. 2007
    ..we investigated the relationship between apoe, mortality and the response to treatment in Mediterranean myocardial infarction (mi) survivors...
  46. ncbi request reprint Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels
    Philipp L Goerttler
    Haematologica 90:851-3. 2005
    ..The results of this retrospective analysis must now be corroborated in a large, prospective trial of newly diagnosed patients...
  47. ncbi request reprint [Chart of the post myocardial infarction risk: results of GISSI-Prevention]
    Roberto Marchioli
    Laboratorio di Epidemiologia delle Malattie Cardiovascolari, Dipartimento di Farmacologia Clinica ed Epidemiologia, Consorzio Mario Negri Sud, S Maria Imbaro, CH
    Ital Heart J 5:86S-90S; discussion 115S-121S. 2004
  48. ncbi request reprint Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
    Raffaele Landolfi
    Catholic University School of Medicine, Institute of Internal Medicine and Geriatrics, Haemostasis Research Center, Rome, Italy
    Blood 109:2446-52. 2007
    ..71; 95% CI, 1.10-2.65; P = .017), mainly deriving from an increased risk of myocardial infarction (HR, 2.84; 95% CI, 1.25-6.46; P = .013). Thus, leukocyte count may help in defining the vascular risk of polycythemic subjects...
  49. doi request reprint Omega-3 fatty acids for cardioprotection
    John H Lee
    Mid America Heart Institute and University of Missouri Kansas City, 4330 Wornall Road, Kansas City, MO 64111, USA
    Mayo Clin Proc 83:324-32. 2008
    ..Blood DHA and EPA levels could one day be used to identify patients with deficient levels and to individualize therapeutic recommendations...
  50. ncbi request reprint Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
    Alessandra Carobbio
    Divisione di Ematologia, Ospedali Riuniti di Bergamo, Bergamo, Italy
    Blood 109:2310-3. 2007
    ..We suggest validation of these findings in prospective clinical studies...